PDCD1 and neoplasm: According to our model, both treatment strategies, cabozantinib and anti-PD1, modulate proteins with a role in tumour cells and the tumour microenvironment including T-cells, myeloid-derived suppressor cells, dendritic cells, macrophages, natural killer cells and vascular endothelial cells.